Pan-Serotype Dengue NS1 Detection for Rapid Test & ELISA Development — Validated Clinical Performance
The Sekbio Dengue NS1 Antibody Pair enables early-phase dengue virus detection via the NS1 (Non-Structural Protein 1) antigen — the primary viremia-phase biomarker for dengue diagnosis. NS1 is secreted into the bloodstream at high concentrations (1–50 µg/mL) during the first 5 days of illness — before antibodies appear — making it the critical target for acute dengue diagnosis during the diagnostic window.
Monoclonal antibody pair designed to capture NS1 from all four dengue serotypes (DENV-1 through DENV-4) without serotype bias. Validated for lateral flow assay (LFA) rapid test development and ELISA sandwich format. Clinical performance data from customer evaluation study available on request.
NS1 antibody pair validated against recombinant and native NS1 from all four dengue serotypes — ensuring detection capability regardless of circulating serotype without reformulation.
NS1 appears in blood before dengue IgM antibodies and peaks at 1–5 days post-fever onset — the critical window for timely dengue diagnosis and clinical management before severe dengue risk escalates.
Monoclonal pair selected for high-affinity NS1 capture across the natural serum concentration range (1–50 µg/mL) — achieving >96% sensitivity in clinical evaluation studies.
Epitope selection minimizes cross-reactivity with related flaviviruses (Zika, West Nile, Yellow Fever) that co-circulate in dengue-endemic regions — critical for specificity in mixed-endemic settings.
Antibody pair tested in both sandwich LFA (colloidal gold) and ELISA plate formats — supporting POCT rapid test and laboratory confirmatory test development from the same raw material.
Stable under tropical storage conditions. Validated in dengue-endemic region clinical samples (SE Asia, Latin America). OEM supply available for regional kit manufacturers.
| Parameter | Performance | Notes |
|---|---|---|
| Clinical Sensitivity | >96% | RT-PCR confirmed dengue positive specimens |
| Clinical Specificity | >99% | Healthy controls + other febrile illness specimens |
| Cross-Reactivity (Zika) | No cross-reaction | Zika NS1 at equivalent concentration |
| Cross-Reactivity (other flaviviruses) | No cross-reaction | WNV, YFV tested |
| NS1 Detection Window | Day 1 – Day 9 | Peak sensitivity Days 1–5 post-symptom onset |
| Full clinical validation dataset available upon request. Contact info@sekbio.com for complete case study report. | ||
| Dengue Serotype | NS1 Detected | Geographic Prevalence |
|---|---|---|
| DENV-1 | ✓ Pan-serotype antibody | SE Asia, Americas, Pacific |
| DENV-2 | ✓ Pan-serotype antibody | Global — most severe serotype |
| DENV-3 | ✓ Pan-serotype antibody | Americas, SE Asia, Africa |
| DENV-4 | ✓ Pan-serotype antibody | SE Asia, Americas, Pacific |
Anti-NS1 pair for colloidal gold LFA test strip — 15-minute dengue NS1 detection at the point of care during the febrile phase (days 1–5) before hospital equipment is needed.
High-sensitivity NS1 ELISA for laboratory confirmation, NS1 quantification research, and blood bank dengue screening using plate-based sandwich ELISA format.
Dengue rapid tests deployed in emergency departments, outpatient clinics, and field settings in SE Asia, Latin America, and Africa — enabling same-visit dengue NS1 triage.
Anti-dengue NS1 monoclonal pair as OEM raw material for rapid test manufacturers entering dengue-endemic markets. Clinical case study data package available for regulatory submissions.
Technical datasheets, performance data, and OEM supply details available on request.